Navigation Links
New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents
Date:11/30/2009

ted the ability to overcome tumor resistance to cisplatin mediated by DNA mismatch repair defects. The complexes showed marked anti-tumor efficacy in platinum refractory tumors, with significant activity in terms of tumor growth inhibition and tumor growth delay.

"Platinum-based compounds are cornerstone agents in the treatment of very common cancers such as cancers of the lung, colon, and ovary and are also widely used in other gynecological tumors, testicular cancers, and cancers of the esophagus, head and neck. They are increasingly being used for salvage therapy in lymphoma. However, resistance to palatinate compounds is common. The current results are encouraging as they demonstrate that the bisplatinates are not only more effective in human tumor models than the current agents, but also capable of overcoming some forms of palatinate resistance," said Jack Singer, M.D., Chief Medical Officer of CTI.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the securities of CTI. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with bis-platinum based compounds in particular,
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pragmedic Implements World-Class Healthcare Solution for Emaar Healthcare
2. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
3. Emergence of Newer Drug Classes to Treat Diabetes and Co-morbidities Key to Market Expansion, Reveals Frost & Sullivan
4. Quantros ACE Helps East Jefferson General Hospital Achieve Best-in-Class Performance
5. BioNeutrals Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms
6. Enerkem Announces World-Class Advanced Energy Research Center in Edmonton, Alberta, Canada
7. CellGard ES NU-480 Class II Biological Safety Cabinet Now Available
8. NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza
9. UKs Institute of Cancer Research and Silicon Graphics Establish Long-Term Alliance to Design and Outfit World-Class Network Biology Lab
10. ACTE Releases Paper Highlighting Policy Trend to Support Recognition of Academic Credit for CTE Classes
11. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 With ... increase of personal health expenditure as well as ... care system, China diagnostic reagent industry has been ... over 90%. In 2013, Chinese in vitro diagnostics ... billion came from in vitro diagnostic reagents. ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Yuma ... facility and complementary therapies brings comprehensive cancer care ... state-of-the-art Yuma Regional Cancer Center has officially opened. ... the program includes services such as open, semi-private ... therapy, American Cancer Society Resource Center, hematology, rehabilitation ...
(Date:7/30/2014)... , July 30, 2014   Epic Sciences, Inc. ... develops novel diagnostics to personalize and advance the treatment ... Gregory T. Lucier as chairman of Epic,s ... CEO of Life Technologies (formerly Invitrogen). Mr. Lucier joins ... commercializes its circulating rare cell analysis platform with special ...
(Date:7/30/2014)... July 30, 2014 Connecticut Center for ... based in East Hartford, Conn., was awarded a Rural ... of a project that will determine the feasibility of ... north-central Connecticut. USDA Rural Development provided $53,000 for CCAT ... the second phase of the feasibility study in fiscal ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3
... PRINCETON, N.J., TOKYO, and REDWOOD CITY, Calif., March ... Inc. (Nasdaq: PDLI ) today announced the ... has acquired PDL,s,rights to IV Busulfex(R) (busulfan), including ... million plus inventory,value., IV Busulfex is an ...
... Calif., March 10 Cepheid (Nasdaq:,CPHD) will present ... March 18 at 10:15 a.m. ET at The ... Chief Executive Officer, will provide a corporate overview., ... may be,accessed on Cepheid,s Web site at ...
... late 2007 ... ... prescribing information for PROCRIT(R) (Epoetin alfa),following guidance from the U.S. Food and ... class., Modifications to the label were based on an unplanned interim ...
Cached Biology Technology:Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 2Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 3Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 4Cepheid to Present at Cowen and Company's 28th Annual Healthcare Conference 2Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 2Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 3Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 4Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 5Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 6Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 7
(Date:7/30/2014)... better decisions about what they eat, the Food and ... to the Nutrition Facts label found on nearly every ... Chemical & Engineering News (C&EN), the weekly news ... updates and the fight that has ensued. , ... that while the Nutrition Facts label has remained largely ...
(Date:7/30/2014)... is a subject of major interest in neuroscience. ... during the distinct stages of Wallerian degeneration: transcription ... dedifferentiation. Although gene expression responses in the distal ... injury are known, differences in gene expression between ... Dengbing Yao and co-workers from Nantong University, China ...
(Date:7/30/2014)... JOSE, Calif. , July 30, 2014 /PRNewswire/ ... partnership with the United States Air Force Research ... proposed by Binghamton University ... human performance monitoring (HPM). The $425,000 project, with ... electronics packaging firm i3 Electronics, Inc. ( ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3
... could see humble cotton thread emerge as a core ... such as kidney failure and diabetes. In a ... and sewing needles to literally stitch,together the uniquely low-cost ... postage stamp. Microfluidic analytical devices, which have been ...
... University of Wisconsin-Madison engineers has developed a highly ... a biomass derivative, into the chemical equivalent of ... 95 percent of the energy from the original ... dioxide under high pressure for future beneficial use. ...
... new University of Colorado at Boulder study shows mice ... with a deadly and poorly understood human inflammatory disease, ... The human disease, known as Hemophagocytic Lymphohistiocytosis, or HLH, ... percent and 90 percent of its victims, said Diane ...
Cached Biology News:How long is a piece of thread? Long enough to save a life 2New process yields high-energy-density, plant-based transportation fuel 2New University of Colorado paper shows novel way to study human inflammatory disease 2
... pLivSelect is a ... for recombinant identification. Recombinant ... colony survival, eliminating the ... screening. This quick and ...
... Signal Enhancer does for enzyme-/substrate-based blotting what intensifying ... the signal up to 10-fold (or one order ... Western Blot Signal Enhancer membrane treatment is a ... to your current Western blotting protocol. The result ...
... multi-functional program that searches for ... sequence file for polymerase chain ... mutagenesis, and various hybridization applications. ... secondary structure of oligonucleotides based ...
...
Biology Products: